Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium tetravaccine
- Development stage
- Phase 4
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium tetravaccine is a probiotic combination product widely used for digestive diseases and the restoration of intestinal flora. It is formulated as oral tablets containing multiple live bacterial strains, typically including Bifidobacterium, Enterococcus faecalis, Lactobacillus acidophilus, and other beneficial microorganisms. The primary mechanism of action involves regulating gut microbiota balance by promoting the growth of beneficial bacteria and inhibiting pathogenic organisms. This helps restore normal intestinal function, improve gastrointestinal motility, enhance immune function, and alleviate symptoms such as abdominal pain, diarrhea, constipation, and bloating. Clinical studies have shown its efficacy in improving nutritional status in patients with stroke and treating functional constipation[1][2][4]. The product is considered safe with a low incidence of adverse effects.
- Brand names
- Siliankang
- Other names
- bifidobacterium tetravaccine tabletsbifidobacterium quadruple viable tablets
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Bifidobacterium tetravaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium tetravaccine.